Linezolid versus Vancomycin for Surgical Site Infection Prevention in Elective Surgeries

What this Trial Is About

Researchers are evaluating the use of linezolid compared to vancomycin as surgical antibiotic prophylaxis to prevent infections in patients undergoing clean elective surgeries. This study focuses on patients allergic to beta-lactams or at risk of infections caused by methicillin-resistant Staphylococcus aureus (MRSA). Surgical site infections can lead to longer hospital stays and increased costs, so finding effective antibiotic options is important for patient care and resistance prevention. The trial compares two groups: one receiving vancomycin at 30 mg/kg infused over 2 hours starting 2.5 hours before surgery, following French guidelines, and the other receiving a 1200 mg dose of linezolid infused over 30 minutes, administered 30 minutes before surgery. Both antibiotics are given intravenously and target Gram-positive bacteria including MRSA. The study includes various elective surgeries such as neurosurgery, cardiac, orthopedic, vascular, and digestive procedures. Participants will be monitored for infection rates 30 days and 365 days after surgery, treatment compliance, hospital stay durations, mortality rates, antibiotic-free days, and infection types. Researchers will also assess costs and quality of life scores during the study period. Safety and effectiveness of the antibiotics will be tracked through clinical evaluations and laboratory results, with participant follow-up lasting up to one year after surgery.

Linezolid or Vancomycin Surgical Site Infection Prophylaxis